SMC accepts vutrisiran for eligible patients in Scotland

RegulatoryapprovedvutrisiranPositive

AI Analysis

Summary

The Scottish Medicines Consortium has accepted vutrisiran, a long-acting therapy targeting the root cause of ATTR-CM, for eligible patients in Scotland. This represents regulatory approval in a key market for the treatment of transthyretin amyloidosis with cardiomyopathy.

Outcome Details

SMC accepts vutrisiran for eligible patients in Scotland

Importance:6/10

Sentiment:

0.80

regulatory approvalScotlandATTR-CMlong-acting therapyrare disease

Related Companies

$ALNY

Read the original article

Published by PharmaTimes on October 12, 2026 9:36 AM

Read Original